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Abstract
Introduction Plasma triglyceride levels are a risk factor for
coronary heart disease. Triglyceride metabolism is well
characterized, but challenges remain to identify novel paths
to lower levels. A metabolomics analysis may help identify
such novel pathways and, therefore, provide hints about
new drug targets.
Objectives In an observational study, causal relationships
in the metabolomics level of granularity are taken into
account to distinguish metabolites and pathways having a
direct effect on plasma triglyceride levels from those which
are only associated with or have indirect effect on
triglyceride.
Method The analysis began by leveraging near-complete
information from the genome level of granularity using the
GDAG algorithm to identify a robust causal network over
122 metabolites in an upper level of granularity. Knowing
the metabolomics causal relationships, we enter the
triglyceride variable in the model to identify metabolites
with direct effect on plasma triglyceride levels. We carried
out the same analysis on triglycerides measured over five
different visits spanning 24 years.
Result Nine metabolites out of 122 metabolites under
consideration influenced directly plasma triglyceride
levels. Given these nine metabolites, the rest of metabolites
in the study do not have a significant effect on triglyceride
levels at significance level alpha = 0.001. Therefore, for
the further analysis and interpretations about triglyceride
levels, the focus should be on these nine metabolites out of
122 metabolites in the study. The metabolites with the
strongest effects at the baseline visit were arachidonate and
carnitine, followed by 9-hydroxy-octadecadenoic acid and
palmitoylglycerophosphoinositol. The influence of arachi-
donate on triglyceride levels remained significant even at
the fourth visit, which was 10 years after the baseline visit.
Conclusion These results demonstrate the utility of inte-
grating multi-omics data in a granularity framework to
identify novel candidate pathways to lower risk factor
levels.
Keywords Metabolomics  Causal network  Genome
DAG  Triglyceride levels  Confounder  Direct effect
1 Introduction
Plasma triglyceride levels are a risk factor for coronary
heart disease (Hokanson and Austin 1996; Fontbonne et al.
1989). Triglyceride levels are negatively correlated with
high density lipoprotein (HDL)-cholesterol levels, and
considerable attention has been placed on therapeutics that
raise HDL-cholesterol levels (Nicholls et al. 2011). Recent
Mendelian randomization studies, however, have cast
doubt on the role of HDL-cholesterol as a causative risk
factor for CHD (Voight et al. 2012) and refocused effort on
triglyceride levels. Triglyceride metabolism is well char-
acterized, but challenges remain to identify novel paths to
lower plasma triglyceride levels. A metabolomics analysis
may help identify such novel pathways and, therefore,
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provide hints about new drug targets. Metabolomics pro-
vides a powerful tool to better understand cellular and
organismal lipid metabolism (German et al. 2007).
The metabolome consists of hundreds of correlated
compounds, and there is considerable information in the
metabolomics network that is not contained in the levels of
individual metabolites (Gao et al. 2010; Karnovsky et al.
2012). Analyses of individual metabolites do not provide
information about likely targets of intervention because of
co-linearity among the metabolites, confounders among
metabolites, and likely untoward effects. Even by fitting
triglyceride on all metabolites simultaneously, the coeffi-
cients cannot be interpreted as true effects due to collinearity.
One approach to directly incorporate relationships among
the metabolome during the analysis of risk factor levels (e.g.
triglycerides) is to consider networks. The importance of
considering biologic networks in relation to human disease
have been widely discussed (e.g. Vidal et al. 2011; Barabasi
and Oltvai 2004). In observational studies, there have been
few practical applications. Some examples of using genomic
variations to identify causal relationships among phenotypes
in observational studies are found in Zhu et al. (2007),
Gomez-Cabrero et al. (2014), Barupal et al. (2012), Inouye
et al. (2010) and Schadt et al. (2005).
In this study, we integrate genomics, metabolomics, and
triglyceride risk factor of disease using the GDAG algorithm.
By integrating data from different granularities and using
knowledge about causal relationship between granularities,
we are able to achieve causal inference that is less susceptible
to confounding by hidden variables and, as a result, estimate
robust causal networks which are well anchored to domain
knowledge. TheGDAGalgorithmextracts information across
the genome to create strong instrumental variables for gen-
erating robust causal relationships among metabolites (Yaz-
dani et al. 2016b). Extracting information across the genome
provides sufficient and reliable information so that there is no
need to limit the number of metabolites under consideration.
Using the genome granularity to identify causal relationships
among metabolomics level of granularity is based on Men-
delian randomization, an established approach to identify
causal relationships. The algorithm then directly incorporates
metabolomics causal relationships during the analysis of
triglyceride levels. Taking the metabolomics causal network
into account and then finding metabolites with direct effects
on triglyceride levels, we can identify confounders at meta-
bolomics level and overcome collinearity amongmetabolites.
Therefore, we can identify novel intervention targets likely to
lower plasma triglyceride levels and perhaps disease risk.
Details of having causal inference in observational studies are
provided in online Appendix 1 (Dawid 2007; Rubin 2005;
Pearl 2009; Yazdani and Boerwinkle 2014). For terminology
in causality see Yazdani and Boerwinkle (2015).
2 Methods
2.1 Study sample and triglyceride measurements
Genomic, metabolomics and triglyceride data were avail-
able on a subset of the Atherosclerosis Risk in Commu-
nities (ARIC) study, a biracial longitudinal cohort of
15,792 middle-aged individuals who were randomly sam-
pled from four US communities and have been measured
for multiple risk factor phenotypes related to health and
chronic disease. A detailed description of the ARIC study
design and methods has been published elsewhere (The
ARIC Investigators 1989). The data presented here
includes 2479 African-American individuals from the
Jackson, MS field center having genomics, metabolomics,
and fasting plasma triglyceride levels.
Common single nucleotide polymorphisms (SNPs) were
genotyped using the Affymetrix platform (version 6.0)
consisting of 1,034,945 common variants spread across the
genome. We reduce the number of SNPs by considering the
fact that some SNPs are nearly perfectly correlated ([0.80)
with others, so that one SNP can thereby serve as a proxy
for many others in the analysis. To determine a proxy, we
use hierarchical clustering and the squared correlation
measure of linkage disequilibrium, for more details see
Yazdani and Dunson (2015). Metabolomics levels were
measured on fasting serum using a combination of gas
chromatography, liquid chromatography, and mass spec-
troscopy. The analysis presented here consists of 122
reliably measured metabolites with low levels of missing
data and normally distributed after transformation.
Triglyceride levels were measured from blood plasma
collected in the fasting state. Triglyceride levels were
measured enzymatically at five different visits during
24 years of follow-up; the serum metabolome was mea-
sured at visit 1. The number of individuals with metabo-
lomics data and examined at each visit is, respectively,
2479, 1920, 1629, 1398 and 700. After winsorising and
taking the logarithm, serum triglyceride levels followed a
normal distribution, which was the variable analyzed here.
2.2 Metabolomics and triglyceride causal network
In this study, we applied the GDAG algorithm, which is a
constraint-based algorithm, to generate a robust causal
network over 122 metabolites under consideration using
genome information. The GDAG algorithm first identifies a
topology (a network without direction) over the variables.
A missing edge between two nodes means the two corre-
sponding variables are independent given the rest of vari-
ables in the model. An edge between two nodes means that
the two corresponding variables are dependent given the
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rest of the variables under consideration. The only tuning
parameter in the GDAG algorithm is significance level,
alpha, which based on preliminary analyses is set to 0.001.
Directionality over the topology which have causal inter-
pretation is then identified using strong instrumental vari-
ables created by extracting information across the genome.
The genome strong instrumental variables identify causal
relationships over the 122 metabolites under consideration.
Online Appendix 2 details this multistep procedure and
online Appendix 3 visualizes the metabolomics causal
relationships.
Next, we integrate metabolomics granularity and
triglyceride variable using the GDAG algorithm. Given the
metabolomics causal network from the previous step, we
enter triglyceride levels into the model. We assess the
direct effect of each metabolite on triglyceride levels given
the metabolomics causal network which directly takes into
account confounders and allows for causal interpretations,
see online Appendix 1 (Yazdani et al. 2016a).
3 Results
Among the 122 metabolites in this analysis, nine metabo-
lites have direct effects on triglyceride levels at visit 1.
Figure 1 depicts the relationship among the nine metabo-
lites with direct effects and ten metabolites with indirect
effect on triglyceride levels. These nine metabolites
directly influenced triglyceride levels after conditioning on
the other metabolites in the study and are circled in red in
online Appendix 3 to show their location in the overall
metabolomics network. Given these nine metabolites, the
rest of metabolites in the study do not have a significant
effect on triglyceride levels at significance level
alpha = 0.001.
We next investigated the effect of the nine metabolites
measured at the baseline examination (i.e. visit 1) on
fasting plasma triglyceride levels measured at each study
visit. Table 1 provides the names and select biologic
characteristics of the nine metabolites ordered by the
p value testing the relationship of each with triglyceride
levels at visit 1. Not surprisingly, the most common
super-pathway is lipid metabolism. None of the nine
metabolites are long chain fatty acids. The metabolite
with the strongest relationship was arachidonate, a
derivative of arachidonic acid. The ARIC study has had
multiple examination from 3 to 15 years apart, and the
metabolomics data were collected at the baseline exami-
nation (i.e. visit 1). The baseline metabolites with the
strongest relationship with triglyceride were arachidonate
and carnitine, followed by 9-hydroxy-octadecadenoic acid
(9-HODE) and palmitoylglycerophosphoinositol. It is of
note that the baseline aracidonate metabolite had a pro-
found relationship with triglyceride levels at each of the
first four visits. There was no metabolite that significantly
influenced triglyceride levels after 24 years at visit 5 (data
not shown).
We measured the effect of each metabolite on baseline
triglyceride levels given the overall metabolomics network.
Details about effect measurement are provided in online
Appendix 1. The results are shown in Table 2. To facilitate
comparison across time and among metabolites, these total
effects are presented in standard deviation units. Glycine,
deoxycarnitine and glutamate had nominal effects on
triglycerides, and these effects were not significant after
adjusting for BMI.




direct effect (shown in orange)
and indirect effect (shown in
pink) on triglyceride (shown in
green) (Color figure online)
A causal network analysis in an observational study identifies metabolomics pathways… Page 3 of 7 104
123
4 Discussion
We analyzed the relationship between a causal network
among 122 serum metabolites and plasma triglyceride
levels with the long-term purpose of identify potential
points of intervention within the metabolome, which may
translate into downstream lowering of triglyceride levels
and possibly reduced risk of cardiovascular disease. In this
analysis, causal inference in an observational study was
facilitated by incorporation of genomic information, which
provided robust direction relationships among the
metabolites. Based on these analyses, we identified nine
metabolites with a significant direct effect on triglyceride
levels. Given these nine metabolites, the rest of metabolites
in the study do not have a significant effect on triglyceride
levels at significance level alpha = 0.001. Therefore, in
this manuscript, we have focused on the presentation and
interpretation of these nine metabolites. Five of the nine
were in the lipid metabolism super pathway, and three of
the nine were in the amino acid super pathway. The four
metabolites with the largest effect on triglyceride were in
the lipid metabolism super pathway. The two metabolites
with the largest effects include arachidonate and carnitine.
The effects of arachidonate on triglycerides remained sig-
nificant 10 years after the original measurement of the
metabolome. Having a causal network between the
Table 1 Metabolites with direct effects on triglyceride levels ordered by the p value at visit 1
Metabolite name Super-pathway Sub-pathway Total effect p value
V1 V2 V3 V4
Arachidonate Lipid Long chain fatty acid 2.3e-17 1e-10 7.3e-9 3.2e-9
Carnitine Lipid Carnitine metabolism 1.4e-11 8.7e-3 6.5e-3 3.6e-3
9-HODE Lipid Fatty acid, monohydroxy 1.4e-7 2.3e-4 5.6e-3 2.7e-3
Palmitoylglycerophos-phoinositol Lipid Lysolipid 1.6e-6 1.4e-3 7.6e-3 5.9e-3
Urate Nucleotide Purine metabolism, urate metabolism 2.2e-5 8.3e-5 4.7e-4 5.9e-3
Isovalerylcarnitine Amino acid Valine, leucine and isoleucine metabolism 2.0e-4 7.6e-3 9.5e-2 8.7e-2
Glycine*(–) Amino acid Glycine, serine and threonine metabolism 3.4e-3 4.7e-3 2.4e-3 8.6e-3
Deoxycarnitine*(–) Lipid Carnitine metabolism 1.1e-3 1.2e-3 4.7e-3 5.3e-3
Glutamate* Amino acid Glutamate metabolism 4.1e-3 2.3e-3 2.4e-3 2.1e-3
– Metabolite with an inverse relationship with triglyceride levels
* Metabolite with no significant effect at level 0.001 after adjusting for BMI
Table 2 Metabolites with direct effect on triglycerides ordered by their effect sizes at visit 1
Metabolite name Super-
pathway
Sub-pathway Total effecta (SE)
V1 V2 V3 V4
Arachidonate Lipid Long chain fatty acid 0.17 (0.03) 0.13 (0.02) 0.16 (0.05) 0.18 (0.03)
Carnitine Lipid Carnitine metabolism 0.15 (0.04) 0.09 (0.03) 0.08 (0.03) 0.06 (0.04)
9-HODE Lipid Fatty acid, monohydroxy 0.12 (0.03) 0.12 (0.04) 0.07 (0.02) 0.10 (0.06)
Palmitoylglycerophos-
phoinositol
Lipid Lysolipid 0.10 (0.01) 0.07 (0.03) 0.01 (0.00) 0.06 (0.01)
Urate Nucleotide Purine metabolism, urate
metabolism
0.09 (0.01) 0.09 (0.01) 0.10 (0.03) 0.07 (0.01)
Isovalerylcarnitine Amino acid Valine, leucine and isoleucine
metabolism
0.09 (0.02) 0.08 (0.01) 0.03 (0.03) 0.05 (0.02)
Glycine Amino acid Glycine, serine and threonine
metabolism
-0.09 (0.02) -0.07 (0.01) -0.11 (0.04) -0.07 (0.03)
Deoxycarnitine Lipid Carnitine metabolism -0.08 (0.03) 0.03 (0.02) 0.11 (0.02) 0.09 (0.01)
Glutamate Amino acid Glutamate metabolism 0.07 (0.02) 0.05 (0.01) 0.04 (0.00) 0.03 (0.02)
a Effect sizes measured in standard deviation units to facilitate comparison
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metabolome and triglycerides, as opposed to only corre-
lations, allows one to identify potential points of inter-
vention, either pharmacologic or genetic, that would be
predicted to alter triglyceride levels. Traditionally, such
causal inference would only be possible in a clinical trials
setting, but the GDAG approach implemented here permits
such predictions in an observational setting.
In the current analysis, by integrating data from different
biological hierarchies, we were able to derive causal
inference that is less susceptible to confounding by hidden
variables and, as a result, estimate robust causal network
over metabolites in the analysis. We then applied the
metabolomics network to find metabolites with direct
effect on triglyceride levels. Multiple previous studies have
used both a priori defined and data-driven networks to
analyze metabolomics data (Gao et al. 2010; Karnovsky
et al. 2012; Grapov et al. 2015; Bartel et al. 2013; Krum-
siek et al. 2011). To our knowledge, this is the first
application that connects genomics, metabolomics, and risk
factors in an observational setting.
The metabolite with the largest effect on triglycerides is
arachidonate, which in vivo is often esterified to a glyc-
erophospholipid. Arachidonate is released from the phos-
pholipid by phospholipase A2-catalzyed hydrolysis. Lp-
PLA2 along with triglycerides are major determinants of
small dense LDL, a major cardiovascular disease risk
factor. In hamster feeding experiments, addition of
arachidonic acid to the diet increases blood triglyceride
levels (Whelan et al. 1995). In humans, there is consider-
able interest in the role of brain arachidonic acid in
membrane function and as a precursor for eicosanoids.
Infants fed arachidonic acid as a triglyceride or phospho-
lipid had increase brain and other organ arachidonic acid
accretion (Wijendran et al. 2002). The causal network
among metabolites allows a more nuanced analysis of their
effect on triglyceride levels compared to a simple pairwise
analysis. Looking at Fig. 1, arachidonate also influences
triglycierides indirectly via its relationship with palmi-
toylglycerophosphoinositol. These multiple paths magnify
the effect any intervention on archidonate would have on
triglyceride levels.
The metabolite with the second largest predicted impact
on triglyceride levels was carnitine. Carnitine aids in the
transport of fatty acids into the mitochondrial matrix during
the break down of lipid on its way to making energy. There
is already considerable literature that dietary supplemen-
tation with carnitine altering blood triglyceride levels in a
number of settings (Bell and DeLucia 1984; Vacha et al.
1983; Ku¨nnert et al. 1983). In some ways then, carnitine
serves as an internal positive control for the current study,
and it is reassuring that the GDAG approach identified a
direct relationship between carnitine and triglycerides.
9-HODE is a product of free radical oxidation of linoleic
acid and is an agonist of PPARc. 9-HODE is a biomarker
of oxidative stress (Fruhwirth et al. 2007). There are many
sources of 9-HODE, including lipoprotein lipase-mediated
lipolysis of triglycerides (Wang et al. 2009). In addition,
there are multiple paths by which 9-HODES may be
involved in the development of atherosclerosis and risk of
CHD, including oxidized LDL, HDL metabolism and
PPARc action. These same paths and players are likely
involved in the relationship between 9-HODES and plasma
triglyceride levels. There are interventions that would
directly impact 9-HODE. PPARc agonists decrease HODE
levels in obese diabetic patients (Popkin and Gordon-Lar-
sen 2004). To our knowledge, the effect of up or down
regulation of lipoprotein lipase or naturally occurring
lipoprotein lipase deficiency on 9-HODE levels have not
been reported.
There is little available about the function of palmi-
toylglycerophosphoinositol, and nothing to our knowledge
about its relationship with triglycerides. The data presented
here, therefore, shed needed light on this portion of the
human serum metabolome. In contrast, there is a consid-
erable knowledgebase on the relationship between uric acid
and triglycerides. Large observational studies support a
positive relationship between uric acid levels and triglyc-
eride levels, and some have argued this is due to a shared
effect of dietary sugar intake (Hofmann and Tscho¨p 2009).
In addition, smaller intervention studies support a positive
relationship. For example, use of fenofibrate, a PPARa
agonist, reduces both blood triglyceride and uric acid
levels, presumably through increased fatty acid b oxidation
(Patterson et al. 2009). The data presented here from causal
inference of the human serum metabolome further supports
this important link.
4.1 Concluding remarks
In summary, the analyses and results presented here are
significant for three reasons. First, they document the
utility of the GDAG algorithm for generating robust and
informative networks among the components of the
serum metabolome and reduce the number of metabolites
that we need to focus on for further analysis of the risk
factor under consideration. Second, they used the meta-
bolomics network as a starting point to analyze plasma
triglyceride levels across multiple visits in a large sample
of individuals, and identified nine metabolites with a
direct effect on triglyceride levels. And third, these
results move us one step closer to identifying novel
points or pathways of intervention to lower plasma
triglyceride levels and possible cardiovascular disease
risk.
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